Contracts › 75N93019F00131
75N93019F00131: This Task Order Is for the Development of a Protocol, Clinical Trial Implementation, Closeout and Analysis of a Phase 2 Clinical Trial to Evaluate the Efficacy of Rmenb+Omv Nz (BEXSERO, GSK) in Preventing N. Gonorrhoeae Infection.
Awarded to University of Alabama at Birmingham by National Institutes of Health (NIH).
$8.8Mobligated
$12.2Mpotential value
31 October 2026current end date
See modifications, all subcontractors and funding in FedSift →
| Contract | 75N93019F00131 |
|---|---|
| Vehicle | HHSN272201300012I |
| Awardee | University of Alabama at Birmingham |
| Awarding agency | National Institutes of Health (NIH) |
| Awarding office | NATIONAL INSTITUTES OF HEALTH NIAID |
| NAICS | 541711 Research and Development in Biotechnology |
| PSC | AN12 Health R&D Services; Health Care Services; Applied Research |
| Place of performance | AL |
| Offers received | 3 |
| Period of performance | 23 August 2019 to 31 October 2026 |
| Potential end | 31 October 2026 |
| Estimated recompete solicitation | Now / imminent (estimate, ~6 months before expiry) |
Source: USASpending.gov (FPDS), public federal procurement data, as the agency reported it. Our record updated 04 October 2026. The solicitation date is an estimate from the end date, not a posted date.
Other expiring 541711 contracts · All expiring contracts · USASpending record